Organovo to market tissue testing service in Japan
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Organovo Holdings Inc. engaged Cosmo Bio Co. Ltd. to market and distribute its NovoView preclinical services in Japan.
The company will work with Cosmo's drug discovery services team to further its 3D bioprinting technology for testing kidney and liver tissue.
